EACPT Focus Meeting 2014

 

Job Position

 Full Professor of Clinical Pharmacology (key chair) Department of Pharmacology and Toxicology at Radboud University Nijmegen Medical Center.

Employment contract of indefinite duration; professorship appointment for 5 years with possibility of extension.

See details in the attached file.

Professor Adam Vas, MD, PhD †

The European Association for Clinical Pharmacology and Therapeutics mourns its Honorary President, Professor Adam Vas, who passed away on July 3rd 2014 at the age of 62 years, after a long illness. The Association has lost a highly distinguished scientist, an advocate of Clinical Pharmacology and a tremendously active EACPT board member.

Adam Vas was born in 1952 in Budapest, Hungary where he trained as a medical doctor at the Semmelweis Medical University. He graduated in 1977 and became a specialist in Internal Medicine and in Clinical Pharmacology, receiving a PhD in 1990 for investigations of liver metabolism. Later he spent several months abroad at the Universities of Bern in Switzerland and Newcastle in the UK, and at the Karolinska Institute in Stockholm. Adam Vas joined the Chemical Works of Gedeon Richter Ltd. Budapest in 1993 as Research Director and was until presently the Senior Research Adviser to the CEO. He became full Professor of Medicine at the Szeged University in 2006 and was Head of the Hypertension Clinic of the St. Emerich Hospital in Budapest.

With great enthusiasm Adam Vas worked hard to promote development of the discipline of clinical pharmacology. He had served for the EACPT since 2003, first as Councillor on the EACPT board, and from 2007-2011 as Treasurer. In 2011 he hosted the successful 10th EACPT congress in Budapest after which he was appointed an Honorary President of the Association. In addition, Adam Vas was the current President of the Hungarian Society for Experimental and Clinical Pharmacology and served on several further scientific boards.

Despite all his merits, Adam Vas remained a modest man, who was always open to giving advice and help. The EACPT loses a warm-hearted and very good friend who will remain in our hearts in grateful remembrance. Our sincere condolences go to his wife Gabriella and to his family.

Prof. Gonzalo Calvo, EACPT Chairman             Prof. Ingolf Cascorbi, EACPT Past Chairman

On behalf of the EACPT Board

CardioVascular Clinical Trialists

 

Drug Discovery of the Year 2015 opens for nominations

 
21 May 2014, London UK: The British Pharmacological Society is now accepting nominations for its thirdDrug Discovery of the Year award. The award was established by the Society in 2012 to demonstrate the importance of pharmacology in the development of new medicines, and to reward the achievements of the teams of scientists who discover and develop these drugs.
 
Previous winners
Drug Discovery of the Year 2013: the Genentech team who developed vismodegib
Drug Discovery of the Year 2014: the GlaxoSmithKline team responsible for trametinib
 
Professor Humphrey Rang, BPS President, comments: “The British Pharmacological Society was encouraged by the exceptional quality of the nominations received last year. I am delighted to announce the call for submissions to our third Drug Discovery of the Year award and to welcome nominations from across all disease areas that demonstrate the importance of both pre-clinical and clinical pharmacology in translating early discoveries into medicines that benefit patients.”
 
The Society’s Industry Committee will consider nominations for the discovery team behind a drug – whether a large or a small molecule – that best fulfils the following criteria:
· preclinical to clinical translation shows the importance of both preclinical and clinical pharmacology in the drug discovery/development process
· gained regulatory approval within the last three years in the EU and/or US
· has a significant impact on an unmet medical need
· first-in-class, or is a significant improvement over other drugs in the class
· mechanism of action known
 
Nominations must be received by 1 October 2014. The winning team will be publicly announced during the Society’s flagship meeting Pharmacology 2014, held in London on 16-18 December 2014, and attended by an anticipated 1,000 pharmacologists.
 
The award does not promote the administration, consumption, prescription, purchase, recommendation, sale, supply or use of the winning medicine; nor does it pre-empt any regulatory decisions. Further information is available from www.bps.ac.uk
 
Kind regards
 
Jan Usher
EACPT

First European Therapeutic Drug Monitoring Conference

Abstract submission deadline of IATDMCT European conference of TDM is extended to 31 May 2014.

Dear colleagues,

It is my honour and pleasure to invite you to the first European Therapeutic Drug Monitoring Conference, which be organised by the Czech Society of Clinical Pharmacology in cooperation with International Association of Therapeutic Drug Monitoring and Clinical Toxicology.
It will be held at the Diplomat Hotel in Prague, Czech Republic on August 28-30, 2014. This meeting will fill the void between the world conferences and will have a shorter programme and different selection of themes. The main focus will be on personalised pharmacotherapy, both in traditional areas (antibiotics, immunosuppressants, anticonvulsives, and cardiovascular drugs) and in new ones such as anticoagulants or nutraceutics. The conference will also focus on pharmacotherapy in pregnancy and breastfeeding, TDM in the elderly, and on the relationship between TDM, phenotyping, and genotyping and their significance for clinical practice.
As is customary at such conferences, analytical methods will be an important part of the programme; we however plan to focus more on interpretation and reporting, hoping to organise the conference for, and in cooperation with, the clinicians who are an indispensable part of the TDM process and whose feedback is essential for the success of our work.
The conference will be held in the very heart of Europe, in Prague, renowned worldwide not just for its beauty but also for its hospitality.
It is my pleasure to invite you to this conference and to the Czech Republic.

On behalf of the organising committee
Assoc. Prof. Milan Grundmann, M.D., Ph.D.
Conference President

Drugs to Fight Cardiovascular Damage

July 3-5 2014, EACPT organizes the 2014 EACPT focus meeting 'Drugs to Fight Cardiovascular Damage'. 

Location:  Radboud university medical center, Nijmegen, the Netherlands. 

Targeted audience: clinical pharmacologists, pharmacologists, (junior) scientists and clinicians interested in drug treatment of cardiovascular disease. 

Topics include: ultrasound imaging of vascular injury (including workshop to get hands-on training), microbioma and inflammation in metabolic syndrome, targeting inflammation to prevent and treat atherosclerosis, diagnosis and therapy of adrenal hypertension, protection against  ischemic-reperfusion injury.

Apart from state of the art lectures by invited speakers, academic and industrial scientists are cordially invited to submit their latest scientific results for oral or poster presentation.

For more information: rvanhugten@kenes.com.

Policy and Pharmacology

Attached is the article on the policy context for EACPT, which appeared in the Autumn 2013 seventh edition of the policy community publication Science & Technology.

Innovative Medicines Initiative

There is a presentation about the summary of activities of the Innovative Medicines Initiative (IMI1) and the future plans for IMI2.

EACPT Statement regarding the EU Clinical Trials Directive 2001/20/EC

see Attachment